- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilar Articles for the Week of June 21
Here are the top 5 biosimilar articles for the week of June 21, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of June 21, 2021.
Number 5: The Supreme Court ruled that plaintiffs had no standing to challenge the constitutionality of the Affordable Care Act, saving the Biologics Price Competition and Innovation Act (BPCIA), which is the regulatory pathway for biosimilar approvals.
Number 4: Sophia Z. Humphreys, PharmD, MHA, explained how biosimilar utilization management can enable health care institutions to put COVID-19–related financial wreckage behind them.
Number 3: Real-world studies demonstrated comparable safety for trastuzumab biosimilars (Kanjinti and Zedora) vs the originator (Herceptin) and were presented at the ASCO 2021 Annual Meeting.
Number 2: Positive findings were reported for use of a bevacizumab biosimilar (Byvasda) in combination with sintilimab as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC).
Number 1: The “winner-takes-all” tender process for biosimilar procurement in the European Union runs the risk of driving competitors out of the market, authors of a new survey contended.
To read all of these articles and more, visit centerforbiosimilars.com.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
FDA's Expanded Access: From Laetrile to Right to Try, Ethical Debates Over Early Drug Access
April 28th 2025Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA approval, highlighting the crucial role of clinical trials and ethical safeguards at the 2025 Festival of Biologics USA.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
